2011
OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.Peer-Reviewed Original ResearchMedian progression-free survivalMetastatic breast cancerProgression-free survivalAI therapyPostmenopausal womenMetastatic diseaseAI-resistant metastatic breast cancerResistant metastatic breast cancerAdjuvant AI therapyAI-resistant diseaseClinical benefit ratePrior chemotherapy regimenPhase II studyAdverse event ratesAddition of bortezomibHuman breast cancer cell linesEstrogen-receptor positiveRandomized phase II designsBreast cancer cell linesPhase II designUnfolded protein responseChemotherapy regimenEligible patientsMeasurable diseasePrior chemotherapy
2009
Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm.
Germain D, Bahadur U, Halpern M, Adelson K, Raptis G, Waxman S, Ishii Y. Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm. Cancer Research 2009, 69: 5142-5142. DOI: 10.1158/0008-5472.sabcs-09-5142.Peer-Reviewed Original ResearchEfficacy of fulvestrantEstrogen receptorAromatase inhibitorsBreast cancer mouse modelPost-menopausal womenCancer mouse modelProteasome inhibitor bortezomibUnfolded protein responseEndometrial cancerPremenopausal womenFulvestrant resistanceStandard treatmentTamoxifen resistanceFulvestrant treatmentTumor regressionAgonist effectsClinical trialsBreast cancerMouse modelFulvestrantTherapeutic benefitConverts androgensAdipose tissueInhibitor bortezomibBortezomib